Earnings Feed

PINC

Healthcare

Adjusted EPS for fiscal 2025 was $1.54, $0.11 above the high end of guidance.
Completed $200 million accelerated share repurchase in August, totaling $800 million repurchased under $1 billion authorization.
Fiscal 2025 full year net revenue was $986 million, $11 million above midpoint guidance.
Free cash flow for fiscal 2025 was $181 million, with a 69% conversion rate, down $48 million year-over-year.
GAAP net income and EPS from continuing operations were $18 million and $0.22 per share, down year-over-year.
Q4 adjusted EBITDA was $71 million with a margin of 27.6%, flat sequentially and better than expected.
Q4 net revenue was $258 million, up 1% sequentially but down year-over-year due to fee share renewals.
Quarterly dividends totaled $77 million in fiscal 2025, representing a nearly 4% dividend yield.

LQDA

Healthcare

Expenses aligned with expectations as the company fully transitioned into commercialization mode.
Liquidia closed Q2 2025 with $173 million in cash and cash equivalents, supporting ongoing commercialization and pipeline investments.
Q2 revenue totaled $8.8 million, including $6.5 million from YUTREPIA product sales and $2.3 million from treprostinil injection promotion services with Sandoz.
R&D expenses are expected to increase in the second half of 2025 due to ongoing label studies and initiation of the pivotal L-606 study.
SG&A expenses, excluding noncash and variable treprostinil costs, are expected to remain flat in upcoming quarters.